Holen Sie sich die Stockscreener-App
21.14
1.40%
-0.30
Vorhandelsmarkt:
21.44
0.30
+1.42%
Schlusskurs vom Vortag:
$21.44
Offen:
$21.325
24-Stunden-Volumen:
3.31M
Relative Volume:
0.78
Marktkapitalisierung:
$7.36B
Einnahmen:
$3.05B
Nettoeinkommen (Verlust:
$181.32M
KGV:
56.68
EPS:
0.373
Netto-Cashflow:
$186.11M
1W Leistung:
+3.22%
1M Leistung:
+4.65%
6M Leistung:
+65.16%
1J Leistung:
+102.68%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$19.93
$21.68
52-Wochen-Spanne:
$9.99
$21.68
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Compare AMRX vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
21.14 | 7.36B | 3.05B | 181.32M | 186.11M | 0.373 |
TAK
Takeda Pharmaceutical Co Adr
|
20.15 | 64.37B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.97 | 46.62B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.00 | 43.98B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
77.80 | 32.15B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
586.48 | 25.15B | 3.17B | 1.29B | 1.01B | 27.09 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-23 | Eingeleitet | Oppenheimer | Outperform |
| 2026-09-09 | Eingeleitet | Leerink Partners | Outperform |
| 2026-04-17 | Eingeleitet | UBS | Buy |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-02-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy? - Zacks Investment Research
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
Parabilis Medicines, Inc. (PBLS) Stock Price & News - Syfe
Curis raises $8.5M via stock and warrant sale t... - Pluang
KNSA Stock Price, Quote & News - Syfe
Generate Biomedicines, Inc. (GENB) Stock Price & News - Syfe
Ionis Pharmaceuticals, Inc. (IONS) Stock Price & News - Syfe
LGND Stock Price, Quote & News - Syfe
Liquidia Corporation (LQDA) Stock Price & News - Syfe
Form 4 Amneal Pharmaceuticals Inc Class A For: 23 September By Investing.com - Investing.com Canada
Form 4 Amneal Pharmaceuticals Inc Class A For: 23 September By Investing.com - Investing.com UK
Form 4 Amneal Pharmaceuticals Inc Class A For: 22 September By Investing.com - Investing.com Nigeria
Form 4 Amneal Pharmaceuticals Inc Class A For: 22 September By Investing.com - Investing.com UK
Form 4 Amneal Pharmaceuticals Inc Class A For: 22 September By Investing.com - Investing.com Canada
Amneal Pharmaceuticals Director Kevin J. Buchi Transfers 20,445 Shares to Trust - Kalkine Media
Amneal (NASDAQ: AMRX) director gifts 20,445 shares to trust he oversees - Stock Titan
Kentucky Gov. Andy Beshear visits Amneal's Glasgow facility - goSkagit
Kentucky Gov. Andy Beshear visits Amneal's Glasgow facility - postregister.com
Amneal Pharmaceuticals, Inc.Class A Common Stock (NQ: AMRX - The Chronicle-Journal
Leerink Partners Initiates Coverage on Amneal Pharmaceuticals With Outperform, $23 Price Target - marketscreener.com
Bausch Health Companies Inc (BHC) Stock Price & News - Syfe
Does Amneal’s New US$523 Million Shelf Registration Reframe Its Capital Allocation Story for AMRX? - simplywall.st
Does Amneal’s New US$523 Million Shelf Registration Reframe Its Capital Allocation Story for AMRX? - simplywall.st
Does Amneal’s Post‑Earnings Shelf Registration Reshape the Bull Case for Amneal Pharmaceuticals (AMRX)? - Yahoo Finance
Amneal Pharmaceuticals (AMRX) Bets Big On Biosimilars While Wall Street Retreats - Yahoo Finance
Amneal Pharmaceuticals (AMRX) Stock Sees Modest Fair Value Lift On Launch Optimism - Yahoo Finance
US FDA is working with manufacturers to boost estrogen patch supply amid access concerns - Reuters
Amneal Pharmaceuticals files prospectus for sale of up to 28.9 million shares - scanx.trade
Amneal Pharmaceuticals (AMRX) Following Its Biosimilars Push And The Fair Value Debate - simplywall.st
Generic Pharmaceuticals Stocks Q2 Results: Benchmarking Amneal (NASDAQ:AMRX) - Yahoo Finance
Amneal Pharmaceuticals Says US FDA Approves Romidepsin Injection Solution - Moomoo
ZLAB Stock Price, Quote & News - Syfe
Parabilis Medicines, Inc. (PBLS) Stock Price & News - Syfe
J.P. Morgan Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $22 - Moomoo
Amneal builds end-to-end biosimilars capacity in the U.S. - chaindrugreview.com
Amneal Pharmaceuticals (AMRX) Stock Looks Fairly Valued But Earnings Still Look Rich - sahmcapital.com
Amneal (AMRX) Results Review: Profit Per Share Clears Its Benchmark in Latest Trading; Closing Reaction: The Share Price Adds 1.87% in the Current UpdateProfit Warning Alert - vinanet.vn
Amneal (AMRX) Earnings Report: EPS Beats Its Estimate in Latest Trading; The Market Price Declines 1.25% in the Latest SessionDiluted EPS Report - vinanet.vn
STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm - Business Wire
Zacks.com featured highlights include CareDx, Healthcare Services, Forum Energy Tech, Amneal Pharma and Caterpillar - Yahoo Finance
Amneal (AMRX) Stock Looks Fairly Valued Following Raised 2026 Guidance - Sahm
Is Amneal Pharmaceuticals (AMRX) Fairly Valued After A 3.5x Return? - Yahoo Finance
AMRX Q2 2026 Earnings: Strong EPS Beat Drives 5.1% RallyEarnings Revision Upgrade - vinanet.vn
Amneal Pharmaceuticals Director John Kiely Sells 50,000 Shares and Donates 10,000 Shares on August 13, 2026 - Kalkine Media
A Look at Amneal Pharmaceuticals Inc (AMRX) After 5.1% Gain -- G - GuruFocus
Insider Selling: Amneal Pharmaceuticals (NASDAQ:AMRX) Director Sells $882,000.00 in Stock - MarketBeat
Amneal Pharmaceuticals (AMRX) director sells 50,000 shares, gifts 10,000 to charity - Stock Titan
Sell Alert: Nikita Shah Cashes Out $2.56M In Amneal Pharmaceuticals Stock - Benzinga
Amneal Pharmaceuticals(AMRX.US) Officer Sells US$3.77 Million in Common Stock - Moomoo
Nikita Shah Sells 146,403 Shares of Amneal Pharmaceuticals (NASDAQ:AMRX) Stock - MarketBeat
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Amneal Pharmaceuticals Inc-Aktie (AMRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kiely John | Director |
Aug 13 '26 |
Sale |
17.64 |
50,000 |
882,000 |
210,252 |
| JOHN KIELY | Director |
Aug 13 '26 |
Proposed Sale |
17.59 |
50,000 |
879,714 |
0 |
| NIKITA SHAH | Officer |
Aug 12 '26 |
Proposed Sale |
17.47 |
146,403 |
2,556,975 |
0 |
| Daly Jason B. | EVP, Chief Legal Officer |
Aug 12 '26 |
Sale |
17.40 |
210,000 |
3,654,000 |
35,171 |
| Shah Nikita | Executive Vice President |
Aug 12 '26 |
Sale |
17.51 |
146,403 |
2,563,517 |
253,390 |
| BUCHI J KEVIN | Director |
Aug 11 '26 |
Proposed Sale |
17.31 |
168,573 |
2,917,998 |
0 |
| Daly Jason B. | EVP, Chief Legal Officer |
Aug 11 '26 |
Sale |
17.70 |
6,613 |
117,050 |
245,171 |
| JASON DALY | OFFICER |
Aug 11 '26 |
Proposed Sale |
17.36 |
210,000 |
3,646,285 |
0 |
| Autor Deborah M. | Director |
May 11 '26 |
Sale |
12.94 |
34,819 |
450,558 |
93,660 |
| DEBORAH AUTOR | DIRECTOR |
May 11 '26 |
Proposed Sale |
12.94 |
34,819 |
450,416 |
0 |
6.70%
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):